{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:30:44Z","timestamp":1776331844284,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ajpc.2024.100682","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:38:34Z","timestamp":1716007114000},"page":"100682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["GLP-1 RA for cardiometabolic risk reduction in obesity \u2013 How do we best describe benefit and value?"],"prefix":"10.1016","volume":"18","author":[{"given":"Sant","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajpc.2024.100682_bib0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"19","author":"Singh","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100682_bib0002","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.ajpc.2024.100682_bib0003","series-title":"FDA approves new drug treatment for chronic weight management, first since 2014","year":"2021"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100682_bib0004","first-page":"16","article-title":"High Demand Keeps Some Diabetes Medications in Short Supply: Pharmaceutical companies are experiencing supply chain disruptions and shortages because of the popularity of diabetes drugs used for weight loss","volume":"167","author":"Blank","year":"2023","journal-title":"Drug Topics"},{"key":"10.1016\/j.ajpc.2024.100682_bib0005","series-title":"Should insurance cover wegovy, ozempic and other new weight-loss drugs?","author":"Tu","year":"2023"},{"key":"10.1016\/j.ajpc.2024.100682_bib0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: A review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.ajpc.2024.100682_bib0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ajpc.2024.100682_bib0008","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.ajpc.2024.100682_bib0009","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ajpc.2024.100682_bib0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ajpc.2024.100682_bib0011","series-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the step-hfpef and step-hfpef dm randomised trials","author":"Butler","year":"2024"},{"issue":"10","key":"10.1016\/j.ajpc.2024.100682_bib0012","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ajpc.2024.100682_bib0013","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100682_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ehjcvp\/pvad080","article-title":"FLOW trial stopped early due to evidence of renal protection with semaglutide","volume":"10","author":"Gragnano","year":"2024","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"issue":"0","key":"10.1016\/j.ajpc.2024.100682_bib0015","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"0","author":"Lincoff","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100682_bib0016","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.ajpc.2024.100682_bib0017","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.ajpc.2024.100682_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060172","article-title":"Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: A reanalysis based on regulatory data","volume":"12","author":"Erviti","year":"2022","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.ajpc.2024.100682_bib0019","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.ajpc.2024.100682_bib0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial","volume":"318","author":"Kazi","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2024.100682_bib0021","unstructured":"High Bad Cholesterol (LDL-C) Treatment | Repatha\u00ae (evolocumab). (n.d.). Retrieved April 14, 2024, from https:\/\/www.repatha.com."},{"key":"10.1016\/j.ajpc.2024.100682_bib0022","unstructured":"Research, C. for D. E. and. (2022, October 20). Multiple Endpoints in Clinical Trials Guidance for Industry. FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/multiple-endpoints-clinical-trials-guidance-industry."},{"key":"10.1016\/j.ajpc.2024.100682_bib0023","series-title":"A phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults with obesity (Clinical trial registration NCT05556512)","year":"2023"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667724000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667724000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T12:23:57Z","timestamp":1719059037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667724000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":23,"alternative-id":["S2666667724000503"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2024.100682","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 RA for cardiometabolic risk reduction in obesity \u2013 How do we best describe benefit and value?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2024.100682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100682"}}